Merkel Cell Carcinoma

1. Disease Information

1.1 Concise overview

Merkel cell carcinoma (MCC) is a rare, clinically aggressive neuroendocrine malignancy of the skin that often metastasizes early and has a substantial risk of recurrence after initial treatment (chang2024theroleof pages 1-2, akaike2024merkelcellcarcinoma pages 1-2).

1.2 Key identifiers and coding

• MeSH (Medical Subject Headings): Carcinoma, Merkel Cell (MeSH ID: D015266) as used in ClinicalTrials.gov MeSH mapping for MCC (NCT03747484 chunk 2, NCT03599713 chunk 3).
• ICD-10 / ICD-11: A rare-disease nomenclature analysis notes that in ICD-10 some entities may be “non-coded” or grouped, and that ICD-11 provides more detailed coding, but the MCC-specific ICD-11 code itself is not reliably extractable from the retrieved excerpts here (li2024classificationandepidemiologic pages 2-3). Practical implication: MCC is often captured within broader “skin cancer” categories in legacy ICD-10-based registries, complicating epidemiology and harmonization across datasets (li2024classificationandepidemiologic pages 2-3).
• Orphanet / OMIM / UMLS: The accessed Orphanet/OMIM codes for MCC were not present in retrieved full text; a dedicated Orphanet query is needed (not available in current evidence set) (li2024classificationandepidemiologic pages 1-2).

1.3 Synonyms and alternative names

Commonly used synonyms/labels in the accessed sources include: - “Merkel cell carcinoma” and abbreviation “MCC” (chang2024theroleof pages 1-2, akaike2024merkelcellcarcinoma pages 1-2) - “Cutaneous neuroendocrine carcinoma” (used in rare-disease classification context; mapping to MCC implied but not formally resolved to a code in retrieved excerpt) (li2024classificationandepidemiologic pages 2-3)

1.4 Evidence source type (individual vs aggregated)

Most epidemiology and outcomes evidence in this report is derived from aggregated disease-level sources including cancer registries, clinical trials, and meta-analyses (moraes2024efficacyandsafety pages 5-8, stang2024incidenceandrelative pages 3-5, d’angelo2024firstlineavelumabtreatment pages 3-4).

2. Etiology

2.1 Primary causal factors (current understanding)

A central organizing concept in MCC biology is the dual-etiology model: 1) Virus-driven MCC caused by clonal integration and continued expression of Merkel cell polyomavirus (MCPyV) T antigens, and
2) UV-associated MCC characterized by UV mutagenesis and typically higher tumor mutational burden (TMB) (becker2024merkelcellcarcinoma pages 1-2, fojnica2023anupdatedreview pages 2-4).

A recent immunology-focused review states: “80% of cases are driven by Merkel cell polyomavirus (MCPyV) oncoproteins that must be continually expressed for tumor survival” (jani2023insightsintoantitumor pages 1-2).

2.2 Risk factors

UV exposure and immunosuppression are repeatedly cited as major risk factors (chang2024theroleof pages 1-2, cheng2017merkelcellpolyomavirus pages 1-2). A mechanistic paper explicitly notes: “Risk factors for developing MCC include immunosuppression and UV-induced DNA damage from excessive exposure to sunlight” (cheng2017merkelcellpolyomavirus pages 1-2).

Immunosuppression and aging: Clinical context sources emphasize chronic immunosuppression as a risk factor, and MCC is typically a disease of older adults, with high metastatic propensity (chang2024theroleof pages 1-2, akaike2024merkelcellcarcinoma pages 1-2).

2.3 Protective factors

High-quality protective-factor evidence (e.g., quantified effect sizes for sun protection or immunosuppression mitigation) was not present in the retrieved primary texts. However, because UV exposure is a major risk factor, UV avoidance/protection is a biologically plausible primary prevention strategy (see Prevention section) (cheng2017merkelcellpolyomavirus pages 1-2).

2.4 Gene–environment interactions

The strongest established interaction is that immune competence modulates tumor surveillance in a disease where either (i) viral antigens (MCPyV) or (ii) UV-derived neoantigens provide immunogenic targets; both etiologies are associated with high immunogenicity but differ in antigen source (becker2024merkelcellcarcinoma pages 1-2, jani2023insightsintoantitumor pages 1-2).

3. Phenotypes (Clinical Presentation) + HPO suggestions

3.1 Typical clinical presentation

MCC often presents as a painless, rapidly growing cutaneous nodule on sun-exposed skin: - “painless, flesh-colored, rapidly growing nodule in a sun-exposed area” (chang2024theroleof pages 1-2) - “rapidly growing, red-to-violet nodule on sun-exposed areas” (mistry2021merkelcellcarcinoma pages 1-2)

3.2 Nodal involvement, metastasis, and recurrence

A recent expert commentary summarizes early aggressive behavior: ~45% have lymph node involvement and ~6% have distant metastases at diagnosis (akaike2024merkelcellcarcinoma pages 1-2). The same source states that “approximately 40% of patients experience disease recurrence… typically within 2 years of initial treatment” (akaike2024merkelcellcarcinoma pages 1-2).

3.3 Stage-associated prognosis (temporal/progression phenotype)

In an NCDB-based analysis used for neoadjuvant immunotherapy context, 5-year OS is reported to decline with increasing stage burden: ~40.3% (stage IIIA clinically occult nodes) to ~26.8% (stage IIIB clinically detected nodes) to ~13.5% (stage IV distant metastases) (chang2024theroleof pages 1-2).

3.4 HPO term suggestions (non-exhaustive)

Because MCC is a malignancy, many key “phenotypes” are oncology course features rather than congenital traits. Suggested HPO mappings: - Cutaneous nodule / skin tumor: Skin nodule (HP:0200149), Cutaneous neoplasm (candidate; verify exact HPO label), Rapidly progressive (HP:0003678) (clinical rapid growth) (chang2024theroleof pages 1-2, mistry2021merkelcellcarcinoma pages 1-2) - Pain phenotype: Absent pain / painless lesion (map to “Pain” HP:0012531 as “not present” in structured phenotyping) (chang2024theroleof pages 1-2) - Regional metastasis: Lymphadenopathy (HP:0002716) as a proxy for nodal involvement; “lymph node metastasis” is not a standard HPO term but can be captured via oncology extensions (akaike2024merkelcellcarcinoma pages 1-2) - Distant metastasis: Metastatic neoplasm (candidate term; verify) (akaike2024merkelcellcarcinoma pages 1-2) - Recurrence: Recurrent infections is inappropriate; instead represent as disease-course annotation (not well captured by core HPO). Use clinical data model fields for recurrence timing (akaike2024merkelcellcarcinoma pages 1-2).

4. Genetic/Molecular Information (Mechanisms, pathways, ontology mappings)

4.1 Molecular subtypes: virus-positive vs virus-negative

Virus-positive MCC is typically characterized by MCPyV integration and lower somatic mutation burden, whereas MCPyV-negative tumors are often UV-driven with higher TMB (fojnica2023anupdatedreview pages 2-4, jani2023insightsintoantitumor pages 1-2).

A 2023 biomarker review provides an illustrative contrast where an MCPyV+ case showed TMB 7 mut/Mb vs an MCPyV− case 34 mut/Mb, with MCPyV status assessed by CM2B4 IHC (fojnica2023anupdatedreview pages 2-4).

4.2 Viral oncoprotein dependencies and epigenetic/transcriptional programs

A mechanistic study in MCPyV-positive MCC showed viral small T antigen (ST) recruits MYCL to the EP400 chromatin remodeling/histone acetyltransferase complex, with MYCL and EP400 required for MCC cell viability (cheng2017merkelcellpolyomavirus pages 1-2). This supports a viral-oncoprotein → transcriptional/epigenetic program → tumor maintenance causal chain.

4.3 Immune involvement and immune evasion

MCC is a model tumor for anti-viral tumor immunity because antigens are shared across MCPyV-driven tumors. A review summarizes that shared MCPyV oncoproteins enable measurement of MCC-directed immunity, and notes immune evasion mechanisms including “transcriptional downregulation of MHC expression… and upregulation of inhibitory molecules including PD-L1” (jani2023insightsintoantitumor pages 1-2).

4.4 Tumor microenvironment (TME) features and biomarkers

Exploratory biomarker analysis from the JAVELIN Merkel 200 avelumab trial describes subtype-associated immune context: MCPyV+ tumors with increased M2 macrophages and PD-L1 correlation; and in MCPyV− tumors, higher CD8+ T-cell density appeared associated with response (d’angelo2024biomarkeranalysesinvestigating pages 2-3).

4.5 Pathway ontology suggestions

• GO Biological Process (examples): immune response; negative regulation of T cell activation; antigen processing and presentation; chromatin remodeling; histone acetylation; PI3K signaling (MCC frequently engages PI3K/AKT/mTOR per preclinical review context) (d’angelo2024biomarkeranalysesinvestigating pages 2-3, pedersen2024merkelcellcarcinoma pages 13-14, cheng2017merkelcellpolyomavirus pages 1-2).
• Cell Ontology (CL) candidates: CD8-positive, alpha-beta T cell; macrophage (including M2-like macrophage states); dendritic cell (activated dendritic cells noted in response context) (d’angelo2024biomarkeranalysesinvestigating pages 2-3).
• CHEBI suggestions (therapeutic chemicals): avelumab, pembrolizumab, nivolumab, retifanlimab (biologics; CHEBI may not include all mAbs; use appropriate drug ontologies if needed) (moraes2024efficacyandsafety pages 5-8, d’angelo2024firstlineavelumabtreatment pages 3-4).

5. Environmental Information

5.1 UV radiation

UV-associated DNA damage is a repeatedly cited etiologic component (cheng2017merkelcellpolyomavirus pages 1-2, fojnica2023anupdatedreview pages 2-4).

5.2 Infectious agents

MCPyV is the key infectious agent in a large fraction of MCC cases, and viral oncoproteins must be persistently expressed for tumor survival in virus-driven MCC (jani2023insightsintoantitumor pages 1-2).

6. Mechanism / Pathophysiology (causal chains)

6.1 Virus-driven chain (conceptual)

MCPyV infection → clonal integration and expression of T antigens → perturbation of cell-cycle control (e.g., RB pathway via LT) and activation of epigenetic/transcriptional programs (e.g., ST–MYCL–EP400 complex) → immune evasion (MHC downregulation, PD-L1 upregulation) → tumor persistence and progression (jani2023insightsintoantitumor pages 1-2, cheng2017merkelcellpolyomavirus pages 1-2).

6.2 UV-driven chain (conceptual)

Chronic UV exposure → UV-induced DNA damage → high mutational burden / neoantigen landscape → selection for immune evasion phenotypes and aggressive neuroendocrine carcinoma phenotype → early metastasis/recurrence (cheng2017merkelcellpolyomavirus pages 1-2, fojnica2023anupdatedreview pages 2-4).

7. Anatomical Structures Affected (UBERON suggestions)

7.1 Primary sites

Primary tumor arises in skin (UBERON:0002097) (mistry2021merkelcellcarcinoma pages 1-2).

7.2 Regional and distant spread

• Regional lymph nodes (UBERON:0000029) (nodal involvement common) (akaike2024merkelcellcarcinoma pages 1-2).
• Distant metastasis can involve multiple organs; specific organ distributions were not quantified in the retrieved texts.

7.3 Cell type

Neuroendocrine carcinoma phenotype; cell-of-origin remains debated, with evidence for lineage reprogramming models (ATOH1) in preclinical systems (pedersen2024merkelcellcarcinoma pages 14-15).

8. Temporal Development

8.1 Onset

Predominantly affects older adults; aggressive growth is typical (akaike2024merkelcellcarcinoma pages 1-2, chang2024theroleof pages 1-2).

8.2 Progression and recurrence

• Early metastasis at diagnosis is common (nodal ~45%, distant ~6%) (akaike2024merkelcellcarcinoma pages 1-2).
• Recurrence is frequent: ~40% recurrence, with many distant recurrences within ~2 years (akaike2024merkelcellcarcinoma pages 1-2).

9. Inheritance and Population

9.1 Epidemiology (recent data)

A population-based German registry analysis (North Rhine–Westphalia; 18 million population coverage) reported: - Age-standardized incidence 5.2 per million person-years (men) and 3.8 per million person-years (women) (2008–2021) (stang2024incidenceandrelative pages 3-5). - 5-year relative survival 58.8% in men and 70.7% in women, and “the first two years are particularly critical” (stang2024incidenceandrelative pages 3-5).

A 2024 commentary notes MCC incidence has risen to approximately 3,000 cases annually in the USA (akaike2024merkelcellcarcinoma pages 1-2).

9.2 Germline genetics / inheritance

No Mendelian inheritance pattern is established for typical MCC; most molecular discussion in retrieved sources concerns somatic and viral carcinogenesis rather than germline inheritance.

10. Diagnostics

10.1 Histopathology and immunohistochemistry

A 2023 review describes classic morphology and a practical diagnostic IHC panel: - Morphology: “small, round, and blue undifferentiated cells with high mitotic rate…” (fojnica2023anupdatedreview pages 2-4). - Typical IHC: CK20 positive and neuroendocrine markers synaptophysin and chromogranin-A; usually negative for melanoma markers (S-100, Melan-A, HMB-45), lymphoid markers (LCA), and TTF-1 (helpful vs metastatic small-cell lung carcinoma) (fojnica2023anupdatedreview pages 2-4).

10.2 Imaging and staging

Staging evaluation commonly includes nodal assessment (including SLNB when feasible), and cross-sectional imaging (CT/MRI) and/or PET as clinically indicated (mistry2021merkelcellcarcinoma pages 1-2, chang2024theroleof pages 1-2).

10.3 Biomarkers and liquid biopsy (real-world implementation)

AMERK (MCPyV oncoprotein antibodies): A ctDNA-focused review states: “In these virus-positive cases, MCPyV oncoprotein antibody (AMERK) titers can be used to monitor disease progression, recurrence risk, and response to therapy” and recommends establishing baseline titers within ~3 months of surgery because titers decline after clinically evident disease is eliminated (prakash2023evolvingapplicationsof pages 2-4).

ctDNA (tumor-informed) for MRD/surveillance: The same review summarizes prospective evidence that ctDNA can precede clinically evident recurrence and provides near-term recurrence-risk estimates. In one cited prospective dataset (125 patients; 328 blood samples), recurrence risk within 60 days of a positive ctDNA test was estimated at 57%, while risk after a negative test was 0% within 60 days and 3% from 60–90 days (prakash2023evolvingapplicationsof pages 4-5).

10.4 Differential diagnosis

MCC must be distinguished from metastatic small-cell lung carcinoma; CK20+/TTF-1− pattern supports MCC in appropriate clinical context (fojnica2023anupdatedreview pages 2-4).

11. Outcomes / Prognosis

Key quantitative survival outcomes from recent evidence are summarized in the table artifact below.

Table: This table compiles key quantitative results for Merkel cell carcinoma across epidemiology, prognosis, immunotherapy efficacy, safety, and real-world implementation. It is useful as a compact evidence summary for knowledge-base population and citation tracking.

Additionally, the 2024 JAVELIN Merkel 200 part B report shows overall survival curves (first-line avelumab) and OS stratified by PD-L1 status; these figures support the long-term survival claims and are included as visual evidence (d’angelo2024firstlineavelumabtreatment media 30169c3d, d’angelo2024firstlineavelumabtreatment media a5f140c8).

12. Treatment

12.1 Standard local therapy (locoregional disease)

Local control commonly relies on surgery (wide local excision) and radiotherapy; systemic therapy is driven by stage and recurrence/metastasis risk (chang2024theroleof pages 1-2, fojnica2023anupdatedreview pages 2-4).

12.2 Checkpoint inhibitors (current standard for advanced disease)

Recent evidence strongly supports PD-1/PD-L1 blockade as a mainstay of advanced MCC management: - First-line avelumab (JAVELIN Merkel 200 part B, 4-year follow-up): “4-year OS rate of 38%” and median OS 20.3 months were reported (ESMO Open; May 2024; https://doi.org/10.1016/j.esmoop.2024.103461) (d’angelo2024firstlineavelumabtreatment pages 3-4, d’angelo2024firstlineavelumabtreatment pages 4-6). OS curves are shown in the retrieved figure (d’angelo2024firstlineavelumabtreatment media 30169c3d). - Meta-analysis (2024, BMC Cancer) of PD-1/PD-L1 inhibitors in MCC reported pooled ORR 53.79% and grade ≥3 TRAEs 17.60% (https://doi.org/10.1186/s12885-024-13129-1) (moraes2024efficacyandsafety pages 5-8). - Real-world avelumab (Israel multicenter): real-world response rate 59%, disease-control rate 70%, complete response 37%, and grade 3–4 toxicity 14% (https://doi.org/10.1002/cam4.5890; Apr 2023) (averbuch2023avelumabforthe pages 4-5).

Retifanlimab regulatory note: A 2023 review states retifanlimab-dlwr (anti-PD-1) is FDA-approved (2023) among ICI options for MCC (fojnica2023anupdatedreview pages 2-4).

12.3 Neoadjuvant immunotherapy (emerging real-world uptake)

In an NCDB analysis of MCC with clinically detected regional lymph node metastasis, neoadjuvant immunotherapy use was ~19.7%, with ypT0 in 45.2% and improved overall survival in matched analysis (5-year OS 57% vs 44%) (https://doi.org/10.1245/s10434-024-15478-4; published online June 2024) (chang2024theroleof pages 1-2).

12.4 PD-(L)1 refractory disease (salvage strategies)

A 2024 commentary synthesizing prospective and retrospective data reports that adding ipilimumab (CTLA-4 blockade, often with nivolumab) after PD-(L)1 failure yields ~31–32% response rates, with grade ≥III irAEs in ~29–36%, and that ~70% will not benefit—supporting a major unmet need (https://doi.org/10.1136/jitc-2024-009396; July 2024) (akaike2024merkelcellcarcinoma pages 1-2).

12.5 MAXO term suggestions

• Wide local excision: MAXO:0000004 (Surgical excision; verify exact MAXO label)
• Radiotherapy: MAXO:0000114 (Radiation therapy; verify)
• PD-1/PD-L1 inhibitor therapy: MAXO term for “immune checkpoint inhibitor therapy” (verify exact MAXO term)
• Sentinel lymph node biopsy: MAXO term for staging biopsy (verify)

13. Prevention

13.1 Primary prevention

Because UV-induced DNA damage is a documented risk factor for MCC, UV exposure reduction (sun-protective behaviors) is mechanistically justified, though MCC-specific intervention effect sizes were not available in the retrieved sources (cheng2017merkelcellpolyomavirus pages 1-2).

13.2 Secondary prevention (surveillance / early recurrence detection)

Secondary prevention is an active translational area: - MCPyV oncoprotein antibody (AMERK) titers for virus-positive MCC surveillance (prakash2023evolvingapplicationsof pages 2-4). - Tumor-informed ctDNA for minimal residual disease and early relapse detection; one synthesized prospective estimate suggests a 57% risk of clinically relevant recurrence within 60 days of a positive ctDNA test vs near-zero short-term risk after a negative test (prakash2023evolvingapplicationsof pages 4-5).

14. Other Species / Natural Disease

No naturally occurring, well-characterized MCC analog across non-human species was retrieved in the accessed texts. Veterinary/cross-species MCC-like neuroendocrine tumors may exist but would require targeted veterinary oncology searches.

15. Model Organisms (Preclinical models)

A 2024 review of MCC biology and models highlights: - Strong reliance on transplantable models (cell line xenografts; emerging patient-derived xenografts) for drug testing (pedersen2024merkelcellcarcinoma pages 14-15). - Difficulty generating faithful GEMMs for MCC due to uncertain cell-of-origin; early MCPyV T antigen mouse models often produced epidermal hyperplasia/papillomas rather than neuroendocrine MCC (pedersen2024merkelcellcarcinoma pages 14-15). - ATOH1-driven lineage reprogramming plus sTAg in embryos can generate “small blue cell tumors resembling” MCC and expressing markers including K20 in the clumped/dot-like pattern typical of MCC (pedersen2024merkelcellcarcinoma pages 14-15). - No syngeneic immunocompetent MCC mouse model is currently available per this review, limiting immunotherapy preclinical modeling (pedersen2024merkelcellcarcinoma pages 14-15).

Expert synthesis (2023–2024 emphasis)

Recent literature converges on MCC as an immunogenic cancer with dual etiologies (viral antigens vs UV neoantigens) and a treatment paradigm dominated by immune checkpoint blockade, yet with a substantial fraction of patients (~50%) lacking durable benefit and therefore a persistent need for biomarkers and effective salvage regimens (jani2023insightsintoantitumor pages 1-2, akaike2024merkelcellcarcinoma pages 1-2, d’angelo2024biomarkeranalysesinvestigating pages 2-3). The most practice-changing real-world implementations in 2023–2024 are the expansion of PD-1/PD-L1 inhibitors as standard systemic therapy and the rapid maturation of blood-based surveillance (AMERK in virus-positive disease; ctDNA MRD surveillance particularly valuable for virus-negative disease) (prakash2023evolvingapplicationsof pages 2-4, prakash2023evolvingapplicationsof pages 4-5, d’angelo2024firstlineavelumabtreatment pages 3-4).

Notes on evidence gaps (for knowledge-base completeness)

• MONDO and Orphanet identifiers were not extractable from the retrieved full texts; populate these fields via direct ontology lookup (e.g., MONDO, Orphanet portals).
• Several mechanistic and clinical claims in reviews cite primary PMIDs, but PMIDs were not consistently present in the retrieved excerpts; use DOI-linked PubMed records to backfill PMIDs where required by the downstream knowledge base.

References

1. (chang2024theroleof pages 1-2): Jenny H. Chang, Daphne Remulla, Chase Wehrle, Kimberly P. Woo, Fadi S. Dahdaleh, Daniel Joyce, and Samer A. Naffouje. The role of neoadjuvant immunotherapy in the management of merkel cell carcinoma with clinically detected regional lymph node metastasis. Annals of Surgical Oncology, 31:6079-6087, Jun 2024. URL: https://doi.org/10.1245/s10434-024-15478-4, doi:10.1245/s10434-024-15478-4. This article has 11 citations and is from a domain leading peer-reviewed journal.

2. (akaike2024merkelcellcarcinoma pages 1-2): Tomoko Akaike, Austin J Jabbour, Peter H Goff, Song Y Park, Shailender Bhatia, and Paul Nghiem. Merkel cell carcinoma refractory to anti-pd(l)1: utility of adding ipilimumab for salvage therapy. Journal for ImmunoTherapy of Cancer, 12:e009396, Jul 2024. URL: https://doi.org/10.1136/jitc-2024-009396, doi:10.1136/jitc-2024-009396. This article has 4 citations and is from a domain leading peer-reviewed journal.

3. (NCT03747484 chunk 2): Joshua Veatch. Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer. Fred Hutchinson Cancer Center. 2019. ClinicalTrials.gov Identifier: NCT03747484

4. (NCT03599713 chunk 3): A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201). Incyte Corporation. 2019. ClinicalTrials.gov Identifier: NCT03599713

5. (li2024classificationandepidemiologic pages 2-3): Junfeng Li, Meilin Liu, Han Li, Xin Zhang, Xufei Xiang, Yiping Wang, Shuyi Wang, Jinxiang Han, and Yanqin Lu. Classification and epidemiologic analysis of 86 diseases in china's second list of rare diseases. Intractable & rare diseases research, 13 4:213-226, Nov 2024. URL: https://doi.org/10.5582/irdr.2024.01061, doi:10.5582/irdr.2024.01061. This article has 6 citations.

6. (li2024classificationandepidemiologic pages 1-2): Junfeng Li, Meilin Liu, Han Li, Xin Zhang, Xufei Xiang, Yiping Wang, Shuyi Wang, Jinxiang Han, and Yanqin Lu. Classification and epidemiologic analysis of 86 diseases in china's second list of rare diseases. Intractable & rare diseases research, 13 4:213-226, Nov 2024. URL: https://doi.org/10.5582/irdr.2024.01061, doi:10.5582/irdr.2024.01061. This article has 6 citations.

7. (moraes2024efficacyandsafety pages 5-8): Francisco Cezar Aquino de Moraes, Michele Kreuz, Isabella Christina Amaral de Lara, Artur de Oliveira Macena Lôbo, and Rommel Mario Rodríguez Burbano. Efficacy and safety of pd-1/pd-l1 inhibitors in patients with merkel cell carcinoma: a systematic review and meta-analysis. BMC Cancer, Nov 2024. URL: https://doi.org/10.1186/s12885-024-13129-1, doi:10.1186/s12885-024-13129-1. This article has 15 citations and is from a peer-reviewed journal.

8. (stang2024incidenceandrelative pages 3-5): Andreas Stang, Lennart Möller, Ina Wellmann, Kevin Claaßen, Hiltraud Kajüter, Selma Ugurel, and Jürgen C. Becker. Incidence and relative survival of patients with merkel cell carcinoma in north rhine-westphalia, germany, 2008–2021. Cancers, 16:2158, Jun 2024. URL: https://doi.org/10.3390/cancers16112158, doi:10.3390/cancers16112158. This article has 4 citations.

9. (d’angelo2024firstlineavelumabtreatment pages 3-4): S.P. D’Angelo, C. Lebbé, L. Mortier, A.S. Brohl, N. Fazio, J.-J. Grob, N. Prinzi, G.J. Hanna, J.C. Hassel, F. Kiecker, A. von Heydebreck, G. Güzel, and P. Nghiem. First-line avelumab treatment in patients with metastatic merkel cell carcinoma: 4-year follow-up from part b of the javelin merkel 200 study. ESMO Open, 9:103461, May 2024. URL: https://doi.org/10.1016/j.esmoop.2024.103461, doi:10.1016/j.esmoop.2024.103461. This article has 29 citations and is from a domain leading peer-reviewed journal.

10. (becker2024merkelcellcarcinoma pages 1-2): Jürgen C. Becker, Andreas Stang, David Schrama, and Selma Ugurel. Merkel cell carcinoma: integrating epidemiology, immunology, and therapeutic updates. American Journal of Clinical Dermatology, 25:541-557, Apr 2024. URL: https://doi.org/10.1007/s40257-024-00858-z, doi:10.1007/s40257-024-00858-z. This article has 38 citations and is from a peer-reviewed journal.

11. (fojnica2023anupdatedreview pages 2-4): Adnan Fojnica, Kenana Ljuca, Saghir Akhtar, Zoran Gatalica, and Semir Vranic. An updated review of the biomarkers of response to immune checkpoint inhibitors in merkel cell carcinoma: merkel cell carcinoma and immunotherapy. Cancers, 15:5084, Oct 2023. URL: https://doi.org/10.3390/cancers15205084, doi:10.3390/cancers15205084. This article has 26 citations.

12. (jani2023insightsintoantitumor pages 1-2): Saumya Jani, Candice D. Church, and Paul Nghiem. Insights into anti-tumor immunity via the polyomavirus shared across human merkel cell carcinomas. Frontiers in Immunology, May 2023. URL: https://doi.org/10.3389/fimmu.2023.1172913, doi:10.3389/fimmu.2023.1172913. This article has 9 citations and is from a peer-reviewed journal.

13. (cheng2017merkelcellpolyomavirus pages 1-2): Jingwei Cheng, Donglim Esther Park, Christian Berrios, Elizabeth A. White, Reety Arora, Rosa Yoon, Timothy Branigan, Tengfei Xiao, Thomas Westerling, Alexander Federation, Rhamy Zeid, Benjamin Strober, Selene K. Swanson, Laurence Florens, James E. Bradner, Myles Brown, Peter M. Howley, Megha Padi, Michael P. Washburn, and James A. DeCaprio. Merkel cell polyomavirus recruits mycl to the ep400 complex to promote oncogenesis. PLOS Pathogens, 13:e1006668, Oct 2017. URL: https://doi.org/10.1371/journal.ppat.1006668, doi:10.1371/journal.ppat.1006668. This article has 157 citations and is from a highest quality peer-reviewed journal.

14. (mistry2021merkelcellcarcinoma pages 1-2): K. Mistry, N. J. Levell, P. Craig, N. M. Steven, and Z. C. Venables. Merkel cell carcinoma. Skin Health and Disease, Jun 2021. URL: https://doi.org/10.1002/ski2.55, doi:10.1002/ski2.55. This article has 22 citations and is from a peer-reviewed journal.

15. (d’angelo2024biomarkeranalysesinvestigating pages 2-3): Sandra P. D’Angelo, Céleste Lebbé, Paul Nghiem, Andrew S. Brohl, Thomas Mrowiec, Trent Leslie, Sara Georges, Gülseren Güzel, and Parantu Shah. Biomarker analyses investigating disease biology and associations with outcomes in the javelin merkel 200 trial of avelumab in metastatic merkel cell carcinoma. Clinical Cancer Research, 30:4352-4362, Jul 2024. URL: https://doi.org/10.1158/1078-0432.ccr-23-0395, doi:10.1158/1078-0432.ccr-23-0395. This article has 9 citations and is from a highest quality peer-reviewed journal.

16. (pedersen2024merkelcellcarcinoma pages 13-14): Elisabeth A. Pedersen, Monique E. Verhaegen, Mallory K. Joseph, Kelly L. Harms, and Paul W. Harms. Merkel cell carcinoma: updates in tumor biology, emerging therapies, and preclinical models. Frontiers in Oncology, Jul 2024. URL: https://doi.org/10.3389/fonc.2024.1413793, doi:10.3389/fonc.2024.1413793. This article has 21 citations.

17. (pedersen2024merkelcellcarcinoma pages 14-15): Elisabeth A. Pedersen, Monique E. Verhaegen, Mallory K. Joseph, Kelly L. Harms, and Paul W. Harms. Merkel cell carcinoma: updates in tumor biology, emerging therapies, and preclinical models. Frontiers in Oncology, Jul 2024. URL: https://doi.org/10.3389/fonc.2024.1413793, doi:10.3389/fonc.2024.1413793. This article has 21 citations.

18. (prakash2023evolvingapplicationsof pages 2-4): Varsha Prakash, Ling Gao, and Soo-Jeong Park. Evolving applications of circulating tumor dna in merkel cell carcinoma. Cancers, 15:609, Jan 2023. URL: https://doi.org/10.3390/cancers15030609, doi:10.3390/cancers15030609. This article has 13 citations.

19. (prakash2023evolvingapplicationsof pages 4-5): Varsha Prakash, Ling Gao, and Soo-Jeong Park. Evolving applications of circulating tumor dna in merkel cell carcinoma. Cancers, 15:609, Jan 2023. URL: https://doi.org/10.3390/cancers15030609, doi:10.3390/cancers15030609. This article has 13 citations.

20. (d’angelo2024firstlineavelumabtreatment pages 4-6): S.P. D’Angelo, C. Lebbé, L. Mortier, A.S. Brohl, N. Fazio, J.-J. Grob, N. Prinzi, G.J. Hanna, J.C. Hassel, F. Kiecker, A. von Heydebreck, G. Güzel, and P. Nghiem. First-line avelumab treatment in patients with metastatic merkel cell carcinoma: 4-year follow-up from part b of the javelin merkel 200 study. ESMO Open, 9:103461, May 2024. URL: https://doi.org/10.1016/j.esmoop.2024.103461, doi:10.1016/j.esmoop.2024.103461. This article has 29 citations and is from a domain leading peer-reviewed journal.

21. (averbuch2023avelumabforthe pages 4-5): Itamar Averbuch, Ronen Stoff, Mor Miodovnik, Shlomit Fennig, Gil Bar‐Sela, Alexander Yakobson, Jonathan Daliot, Nethanel Asher, and Eyal Fenig. Avelumab for the treatment of locally advanced or metastatic merkel cell carcinoma—a multicenter real‐world experience in israel. Cancer Medicine, 12:12065-12070, Apr 2023. URL: https://doi.org/10.1002/cam4.5890, doi:10.1002/cam4.5890. This article has 16 citations and is from a peer-reviewed journal.

22. (d’angelo2024firstlineavelumabtreatment media 30169c3d): S.P. D’Angelo, C. Lebbé, L. Mortier, A.S. Brohl, N. Fazio, J.-J. Grob, N. Prinzi, G.J. Hanna, J.C. Hassel, F. Kiecker, A. von Heydebreck, G. Güzel, and P. Nghiem. First-line avelumab treatment in patients with metastatic merkel cell carcinoma: 4-year follow-up from part b of the javelin merkel 200 study. ESMO Open, 9:103461, May 2024. URL: https://doi.org/10.1016/j.esmoop.2024.103461, doi:10.1016/j.esmoop.2024.103461. This article has 29 citations and is from a domain leading peer-reviewed journal.

23. (d’angelo2024firstlineavelumabtreatment media a5f140c8): S.P. D’Angelo, C. Lebbé, L. Mortier, A.S. Brohl, N. Fazio, J.-J. Grob, N. Prinzi, G.J. Hanna, J.C. Hassel, F. Kiecker, A. von Heydebreck, G. Güzel, and P. Nghiem. First-line avelumab treatment in patients with metastatic merkel cell carcinoma: 4-year follow-up from part b of the javelin merkel 200 study. ESMO Open, 9:103461, May 2024. URL: https://doi.org/10.1016/j.esmoop.2024.103461, doi:10.1016/j.esmoop.2024.103461. This article has 29 citations and is from a domain leading peer-reviewed journal.